Natera to Present New Signatera and Empower Data at the 2022 Annual San Antonio Breast Cancer Symposium (Natera Press Release)
"Natera, Inc...plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas...Natera will present two posters from the LEADER and I-SPY 2 clinical trials in HR+, HER2- breast cancer highlighting Signatera's ability to detect recurrence and facilitate treatment response monitoring. A third poster from a multi-center study of over 1,900 patients will describe how hereditary cancer screening with Empower at the time of imaging can help to identify patients who may benefit from cancer risk management."